ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” standing from somewhat much than fractional of the analysts covering the stock. While the terms people ranges from $1 to $12, the median terms people of $6.50 reflects an upside imaginable of 152.92%. Among the analysts bullish connected the banal is Joseph Pantginis, an expert astatine H.C. Wainwright, who assumed sum connected the institution with a ‘Buy’ standing and a $12 terms people connected December 16, according to TheFly. His terms people implies astir 367% upside from the existent price.

With ProKidney Corp. (NASDAQ:PROK) initiating a caller attack to “postponing progressive kidney dysfunction,” the expert believes the company’s pb asset, rilparencel, exhibits the imaginable to redefine however chronic kidney illness is treated.

Likoper/Shutterstock.com

H.C. Wainwright highlighted that rilparencel, an investigational autologous compartment therapy for patients surviving with chronic kidney illness and benignant 2 diabetes, has already demonstrated promising results crossed respective Phase 1 and 2 trials. This includes meaningful advancements successful estimated glomerular filtration complaint (eGFR) drops, a affirmative information profile, and a slowed progression to dialysis.

With that said, the company’s existent Phase 3 PROACT 1 trial, which is wholly successful enactment with its Phase 2 design, has been awarded FDA support for utilizing eGFR slope arsenic a surrogate endpoint. Through an accelerated regulatory support process, this could besides backmost a Biologics License Application (BLA) filing.

ProKidney Corp. (NASDAQ:PROK) is simply a North Carolina-based clinical-stage biotechnology institution that provides a compartment therapy level for treating assorted chronic kidney diseases. Incorporated successful 2015, the institution is committed to “transforming the attraction scenery for chronic kidney disease.”

While we admit the imaginable of PROK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.